Penpulimab access guide: country options for cross-border named-patient access
Editorial and clinical review: Reserve Meds clinical and regulatory team. Last reviewed 2026-06-04.
About Penpulimab
Penpulimab (penpulimab-kcqx) is a programmed death receptor-1 (PD-1) blocking monoclonal antibody approved by the US Food and Drug Administration for metastatic non-keratinizing nasopharyngeal carcinoma (NPC) in combination with chemotherapy as first-line treatment, and recurrent or metastatic NPC after platinum chemotherapy. The current FDA label is available at accessdata.fda.gov. Penpulimab is marketed by Akeso and Sino Biopharm. Reserve Meds coordinates US-sourced cross-border access to Penpulimab under the named-patient and personal-import framework that governs reference-authority-approved medicines in the patient jurisdiction, with chain-of-custody documentation under the US Drug Supply Chain Security Act (DSCSA). The country-specific access guides listed below set out the regulatory pathway, the tertiary referral context, the documentation bundle the treating physician of record submits to the regulator, and the indicative drug-only cash-pay band for Penpulimab in each jurisdiction Reserve Meds has authored.
Penpulimab country-specific access guides
Reserve Meds has published 3 country-specific access guides for Penpulimab. Each guide covers the regulatory pathway, the tertiary referral context, the documentation package, the indicative drug-only band, and the operational sequence Reserve Meds coordinates for that jurisdiction.
Qatar
Read the Qatar access guide for Penpulimab.
Read the guideSaudi Arabia
Read the Saudi Arabia access guide for Penpulimab.
Read the guideSri Lanka
Read the Sri Lanka access guide for Penpulimab.
Read the guideOther countries not yet authored
Reserve Meds has authored country-specific access guides for Penpulimab in the 3 jurisdictions listed above. If your case sits in a country that is not yet on this list, that does not mean a pathway is unavailable. It means we have not yet published the country-specific guide for Penpulimab. The Reserve Meds case team will scope your case under the same named-patient or personal-import framework that governs the published guides.
Request a Penpulimab access scope for your country
Related Reserve Meds resources
Composite case examples; no individual patient is depicted. This content is for general information and does not constitute medical advice. Reserve Meds is a US-based concierge coordinator; we are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating physician.
Editorial review: Reserve Meds clinical and regulatory team. Last reviewed 2026-06-04.
Frequently asked questions
How can I get Penpulimab-kcqx if it is not approved or available in my country?
Reserve Meds coordinates US-sourced Penpulimab-kcqx for patients through a physician-led, named-patient cross-border pathway. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for your country and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Penpulimab-kcqx through named-patient or compassionate-use import?
Yes. Named-patient access (also called compassionate use or personal import) is the core route Reserve Meds operates for Penpulimab-kcqx. Eligibility and paperwork depend on the regulator in your country, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Penpulimab-kcqx through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Penpulimab-kcqx to a patient?
Reserve Meds sources Penpulimab-kcqx from a DSCSA-compliant US specialty supplier with full traceability and coordinates delivery to your treating physician or hospital pharmacy, with appropriate handling for the product.
How long does it take, and what does Penpulimab-kcqx cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Penpulimab-kcqx?
Submit a 60-second intake through the Reserve Meds patient portal, or message the concierge team on WhatsApp. A named coordinator follows up within 24 hours.